晚期肾细胞癌治疗药物temsirolimus的不良反应及处理  

Temsirolimus-related adverse reactions and treatment in patients with advanced renal cell carcinoma

作　　者：王肖[1] 张杰[1] 

机构地区：[1]武汉大学人民医院泌尿外科,武汉430060

出　　处：《世界临床药物》2009年第11期662-665,共4页World Clinical Drug

摘　　要：新药temsirolimus是用于治疗晚期肾细胞癌(RCC)的首个哺乳动物雷帕霉素靶蛋白(mTOR)抑制剂。治疗晚期RCC的Ⅱ/Ⅲ期临床研究显示,temsirolimus对RCC有显著疗效,但同时发现诸多不良反应,以高血糖、高甘油三酯血症、贫血和口腔炎等较常见。现就其给药方法、不良反应及处理作一综述。Temsirolimus is a specific inhibitor of the mammalian target of rapamycin(mTOR) and is the first-in-class mTOR inhibitor for treatment of renal cell carcinoma(RCC).The evidences ofⅡ/Ⅲphase clinical trials indicated that it was effective to RCC.However,there were many adverse reactions related to temsirolimus,the most common temsirolimus-related adverse reactions were hyperglycemia,hypertriglyceridemia,anemia and somatitis.This paper reviews administration,adverse reactions of temsirolimus and its treatment.

关 键 词：肾肿瘤 TEMSIROLIMUS 不良反应 处理 

分 类 号：R979.1[医药卫生—药品]